Cargando…
Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
This cohort study describes patterns of development, management strategies, and long-term vascular consequences of hypertension associated with ibrutinib in the non–clinical trial setting.
Autores principales: | Roeker, Lindsey E., Sarraf Yazdy, Maryam, Rhodes, Joanna, Goodfriend, Julie, Narkhede, Mayur, Carver, Joseph, Mato, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902749/ https://www.ncbi.nlm.nih.gov/pubmed/31790561 http://dx.doi.org/10.1001/jamanetworkopen.2019.16326 |
Ejemplares similares
-
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023) -
Novel-agent combination therapies in chronic lymphocytic leukemia: the law of relative contributions
por: Mato, Anthony R., et al.
Publicado: (2022) -
All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic leukemia
por: Thompson, Meghan C., et al.
Publicado: (2021) -
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
por: Landau, Dan A., et al.
Publicado: (2017) -
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
por: Rhodes, Joanna M, et al.
Publicado: (2021)